Mar 25, 2020 · Abstract. A Rho GTPase-activating protein (RhoGAP), deleted in liver cancer 1 (DLC1), is known to function as a tumor suppressor.

Mar 27, 2020 · Article: Nuclear DLC1 exerts oncogenic function through association with FOXK1 for cooperative activation of MMP9 expression in melanoma.

With regards to the high-dimensional nature of genomic data ... (https://www.cancerrxgene.org/). We specifically ... 10.1038/s41388-020-1274-8 [PMC free article] ...

Sep 28, 2022 · The present study aimed to identify immune-based prognostic ATGs and verify their functions in tumor immune microenvironment (TIME) in GC.

This is a critical review highlighting the role of Rho GTPases in every step of cancer progression. This article also discusses how research in the last three ...

Using in vitro cancer cell line dose-response and gene expression data from the Genomics of Drug Sensitivity in Cancer (GDSC) project, we build a dose-varying ...

(2024) Nature Commun 15 (1): 2229 https://doi.org ... com/articles/s41388-020-1274-8. Behind the paper ... (Highlighted article in the journal homepage) https://www ...

Mar 25, 2020 · A Rho GTPase-activating protein (RhoGAP), deleted in liver cancer 1 (DLC1), is known to function as a tumor suppressor in various cancer ...

Apr 9, 2024 · This fundamental study reports compelling findings that intermediate states exist in epithelial-mesenchymal transition (EMT) during natural ...

Sep 17, 2022 · The present study aimed to identify immune-based prognostic ATGs and verify their functions in tumor immune microenvironment (TIME) in GC.